U.S. markets closed

Ligand Pharmaceuticals Incorporated (LGND)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
82.45-0.62 (-0.75%)
At close: 4:00PM EDT

82.45 0.00 (0.00%)
After hours: 4:00PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close83.07
Open80.51
Bid80.90 x 1800
Ask87.50 x 1400
Day's Range78.26 - 84.64
52 Week Range57.24 - 127.80
Volume547,217
Avg. Volume302,195
Market Cap1.326B
Beta (5Y Monthly)1.44
PE Ratio (TTM)N/A
EPS (TTM)-1.44
Earnings DateOct 30, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJul 02, 2010
1y Target Est181.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Ligand Pharmaceuticals (LGND) Q3 Earnings and Revenues Miss Estimates
    Zacks

    Ligand Pharmaceuticals (LGND) Q3 Earnings and Revenues Miss Estimates

    Ligand (LGND) delivered earnings and revenue surprises of -1.89% and -8.36%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

  • Benzinga

    Recap: Ligand Pharmaceuticals Q3 Earnings

    Shares of Ligand Pharmaceuticals (NASDAQ:LGND) were flat in pre-market trading after the company reported Q3 results.Quarterly Results Earnings per share rose 112.24% year over year to $1.04, which beat the estimate of $0.98.Revenue of $41,848,000 up by 68.69% from the same period last year, which missed the estimate of $44,360,000.Outlook The upcoming fiscal year's EPS expected to be between $6.00 and $6.00.The upcoming fiscal year's revenue expected to be between $285,000,000 and $285,000,000.Details Of The Call Date: Oct 30, 2020View more earnings on LGNDTime: 08:30 AMET Webcast URL: https://engage.vevent.com/index.jsp?eid=7772&seid=77/main/simplifyPrice Action Company's 52-week high was at $127.8052-week low: $57.24Price action over last quarter: down 29.55%Company Profile Ligand Pharmaceuticals is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.See more from Benzinga * Click here for options trades from Benzinga * Earnings Scheduled For October 30, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Ligand Reports Third Quarter 2020 Financial Results
    Business Wire

    Ligand Reports Third Quarter 2020 Financial Results

    Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three- and nine-months ending September 30, 2020 and provided an operating forecast and program updates. Ligand management will host a conference call with slides today beginning at 8:30 a.m. Eastern time to discuss this announcement and answer questions.